Evidence map›Paper›PMID 32029124›Full record

ArticleAnalytica chimica acta2020

Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry.

J S McGrath, C Honrado, J H Moore, S J Adair, W B Varhue, A Salahi, V Farmehini, B J Goudreau, S Nagdas, E M Blais and 2 more

Open access · greenAbstract read
In one paragraph

Article in Analytica chimica acta, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Cell-Based Immuno-Biosensors Using Microfluidics.Sensors (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

J S McGrathSchool of Engineering and Applied Sciences, University of Virginia, Charlottesville, VA, USA.
C HonradoSchool of Engineering and Applied Sciences, University of Virginia, Charlottesville, VA, USA.
J H MooreSchool of Engineering and Applied Sciences, University of Virginia, Charlottesville, VA, USA.
S J AdairDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA.
W B VarhueSchool of Engineering and Applied Sciences, University of Virginia, Charlottesville, VA, USA.
A SalahiSchool of Engineering and Applied Sciences, University of Virginia, Charlottesville, VA, USA.
V FarmehiniSchool of Engineering and Applied Sciences, University of Virginia, Charlottesville, VA, USA.
B J GoudreauDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA.
S NagdasDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA.
E M BlaisDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA.
T W BauerDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA.
N S SwamiSchool of Engineering and Applied Sciences, University of Virginia, Charlottesville, VA, USA. Electronic address: nswami@virginia.edu.
University of Virginia · US

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Exploring the Role of Mitochondrial Fission in Pancreatic TumorigenesisR01CA200755 · NCI · UNIVERSITY OF VIRGINIA · PI KASHATUS, DAVID FRANCIS · 2016 to 2020
$2.2M
Optimizing Inter-Microbial Antagonisms to Control Clostridium Difficile InfectionR21AI130902 · NIAID · UNIVERSITY OF VIRGINIA · PI SWAMI, NATHAN, WARREN, CIRLE ALCANTARA · 2017 to 2018
$413k
NCI NIH HHS L30 CA124093NCI NIH HHS R01 CA200755NCI NIH HHS T32 CA009109NIAID NIH HHS R21 AI130902
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer lacking specific biomarkers that can be correlated to disease onset, promotion and progression. To assess whether tumor cell electrophysiology may serve as a marker for PDAC tumorigenicity, we use multi-frequency impedance cytometry at high throughput (∼350 cells/s) to measure the electrical phenotype of single PDAC tumor cells from xenografts, which are derived from primary pancreatic tumors versus those from liver metastases of different patients. A novel phase contrast metric based on variations in the high and low frequency impedance phase responses that is related to electrophysiology of the cell interior is found to be systematically altered as a function of tumorigenicity. PDAC cells of higher tumorigenicity exhibited lowered interior conductivity and enhanced permittivity, which is validated by the dielectrophoresis on the respective cell types. Using genetic analysis, we suggest the role of dysregulated Na

Indexed as

AdenocarcinomaAnimalsCarcinoma, Pancreatic DuctalCell Line, TumorElectric ImpedanceElectrophysiologyGene Expression Regulation, NeoplasticHeterograftsHumansLiverMiceMicrofluidicsPancreasProto-Oncogene Proteins p21(ras)Single-Cell AnalysisKRAS protein, humanProto-Oncogene Proteins p21(ras)CancerDielectrophoresisImpedance cytometryMicrofluidicsPancreatic ductal adenocarcinoma

Identifiers

PMID32029124
PMCPMC7007881
OpenAlexW2996462026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.